Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all
Not listed No phase listed Observational

DKA Optic Ultrasound

NCT02130180
View directory record Official record
Conditions
Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
7 Years to 18 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis and Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus

NCT04439903
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Web-based Simulation Tool
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study

NCT01892280
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teenwork intervention, Text message reminders
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
13 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet

NCT03443180
View directory record Official record
Conditions
Type1diabetes
Interventions
Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 23 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional

Study of Latiglutenase in T1D/CD Patients

NCT04839575
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

NCT06272695
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Volagidemab
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Deigo, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Recruiting Phase 1 Interventional

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

NCT06919354
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 1 Diabetes Mellitus
Interventions
GNTI-122
Biological
Lead sponsor
GentiBio, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Duarte, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes

NCT01569841
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 16, 2026, 4:03 PM EDT
Not listed Not applicable Interventional

Resistance Training in Type 1 Diabetes Mellitus

NCT05315037
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Resistance Training
Other
Lead sponsor
University of Louisville
Other
Eligibility
13 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 16, 2026, 4:03 PM EDT
Not listed Phase 4 Interventional

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

NCT04414579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Faster Insulin Aspart (Fiasp®)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 16, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

NCT00137046
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Subcutaneous Insulin, Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
36
States / cities
Fullerton, California • Long Beach, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2010 · Synced Oct 16, 2026, 4:03 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
MEDI5752, Axitinib, Lenvatinib
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Fort Myers, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

NCT04848480
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
insulin icodec, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Concord, California • Escondido, California • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 16, 2026, 4:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Imaging of Type 1 Diabetes Progression

NCT01521520
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ferumoxytol
Drug
Lead sponsor
Jason Gaglia
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D

NCT02746627
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Positive Affect, Education
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

Family Management of Type 1 Diabetes in Children

NCT00273286
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
family diabetes management intervention
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
108 Months to 174 Months
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Jacksonville, Florida • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 16, 2026, 4:03 PM EDT
Recruiting Not applicable Interventional

APP-MNT: App-Enhanced Medical Nutrition Therapy on Glycemic Outcomes and Quality of Life

NCT07773779
View directory record Official record
Conditions
Diabetes (Insulin-requiring, Type 1 or Type 2)
Interventions
Undermyfork Care App, Usual Care
Device · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

DailyDose Smart Snack Study for T1D on MDI

NCT05967260
View directory record Official record
Conditions
Type 1 Diabetes Mellitus With Hypoglycemia
Interventions
DailyDose Smart Snack app, Dexcom G6 CGM
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 16, 2026, 4:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neulasta in Type 1 Diabetes

NCT00662519
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Neulasta (Pegylated), Placebo, Mixed Meal Tolerance Test (MMTT), Blood test, DNA Test
Drug · Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
12 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 16, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

NCT02171130
View directory record Official record
Conditions
Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Interventions
Nasal Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Waltham, Massachusetts • Minneapolis, Minnesota • Albany, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 16, 2026, 4:03 PM EDT